Medical Information: +32 460 20 29 27
Scroll to explore
What We Do

Our Therapeutic Areas

Pioneering life-transforming treatments across four key therapeutic areas, improving outcomes for patients worldwide.

Hematology

World-leading treatments for bleeding disorders including hemophilia and other rare blood conditions.

  • Hemophilia A & B treatments
  • Factor replacement therapies
  • Bleeding disorder management
Learn More

Immunology

Advanced immunoglobulin therapies for patients with immune deficiencies and autoimmune conditions.

  • Immunoglobulin therapies
  • Primary immunodeficiency
  • Autoimmune solutions
Learn More

Oncology

Pioneering cancer treatments with focus on targeted therapies and precision medicine approaches.

  • Targeted cancer therapies
  • Precision medicine
  • Oncaspar® for leukemia
Learn More

Rare Diseases

Dedicated research and treatment solutions for patients with rare and orphan diseases.

  • Orphan drug development
  • Lysosomal storage disorders
  • Metabolic conditions
Learn More
View All Services R&D Pipeline
euroPLX Laboratory
10+ Years of Excellence
Who We Are

About euroPLX Pharmaceutical

A global biopharmaceutical leader transforming lives through innovative treatments.

euroPLX Pharmaceutical is a global biopharmaceutical company dedicated to developing life-transforming treatments for patients with rare and serious conditions. We focus on breakthrough therapies in hematology, immunology, and oncology, bringing innovative solutions to patients worldwide.

Our European operations serve as a key hub for global markets, driving innovation and delivering critical therapies to patients across the continent.

  • Global Pharmaceutical Leader
  • European Manufacturing Hub
  • Focus on Rare & Complex Diseases
Learn More About Us
16,000+Global Employees
100+Countries Served
20+Pipeline Projects
1M+Patients Helped

Why Choose euroPLX

🔬

Innovative R&D

🎓

Expert Scientists

🌎

Global Reach

❤

Patient-First Focus

Our Leaders

Leadership Team

Meet the experienced professionals driving innovation and excellence at euroPLX Pharmaceutical.

Dr. Marc Vandenberghe

Dr. Marc Vandenberghe

Chief Executive Officer

Leading euroPLX Pharmaceutical's strategic vision with 25+ years of pharmaceutical industry experience.

Dr. Sophie Laurent

Dr. Sophie Laurent

Chief Scientific Officer

Driving R&D innovation with expertise in hematology and rare disease research.

Thomas Janssen

Thomas Janssen

Chief Financial Officer

Managing financial strategy and sustainable growth across European operations.

Dr. Elena Martens

Dr. Elena Martens

Chief Medical Officer

Overseeing clinical development and medical affairs with patient-centered focus.

Testimonials

What Partners & Patients Say

Trusted by healthcare professionals and patients across Europe

“euroPLX's commitment to hemophilia treatment has transformed how we manage patient care. Their innovative therapies provide better outcomes with fewer infusions.”
Dr. Erik Jansen
Dr. Erik Jansen
Hematologist, University Hospital Brussels
Healthcare Partner
“The patient support programs offered by euroPLX go beyond what any other pharmaceutical company provides. They truly understand the patient journey.”
Marie Dupont
Marie Dupont
Patient Advocate, Rare Disease Alliance
Patient Voice

Trusted by leading institutions across Belgium and Europe

50+ Hospitals
10,000+ Patients
30+ Countries

Our R&D Pipeline

1

Discovery

2

Clinical Trials

3

Regulatory Approval

4

Market Launch